PsA: The Derm Version

Psoriatic arthritis management requires a nuanced approach that balances skin clearance with the prevention of irreversible joint damage. The APEX study demonstrates that the IL-23 inhibitor guselkumab significantly inhibits radiographic progression, providing a potent therapeutic option for patients with active disease. Dr. Saakshi Khattri, a double-boarded rheumatologist and dermatologist from Mount Sinai, emphasizes that dermatologists can effectively treat early psoriatic arthritis, potentially bypassing lengthy rheumatology referral delays when patients respond well to systemic therapy. While insurance mandates often prioritize older, less expensive agents like anti-TNFs or methotrexate, clinicians increasingly favor IL-23 and IL-17 inhibitors for their superior skin and joint efficacy. Age-based stratification remains a critical diagnostic tool, as younger patients with joint pain are more likely to have inflammatory arthritis rather than mechanical osteoarthritis, justifying earlier, more aggressive intervention with advanced biologics to preserve long-term joint function.